Everest Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 13, 2025, 8:45 pm

Competitors of Everest Industries Ltd

All Competitor Stocks of Everest Industries Ltd

Quarterly Result

Last Updated: August 20, 2025, 11:00 am

Below is a detailed analysis of the quarterly data for Everest Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 500.72 Cr.. The value appears strong and on an upward trend. It has increased from 452.63 Cr. (Mar 2025) to 500.72 Cr., marking an increase of 48.09 Cr..
• For Expenses, as of Jun 2025, the value is 484.32 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 442.32 Cr. (Mar 2025) to 484.32 Cr., marking an increase of 42.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 16.40 Cr.. The value appears strong and on an upward trend. It has increased from 10.31 Cr. (Mar 2025) to 16.40 Cr., marking an increase of 6.09 Cr..
• For OPM %, as of Jun 2025, the value is 3.28%. The value appears strong and on an upward trend. It has increased from 2.28% (Mar 2025) to 3.28%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 3.29 Cr.. The value appears to be declining and may need further review. It has decreased from 14.31 Cr. (Mar 2025) to 3.29 Cr., marking a decrease of 11.02 Cr..
• For Interest, as of Jun 2025, the value is 6.45 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.30 Cr. (Mar 2025) to 6.45 Cr., marking a decrease of 0.85 Cr..
• For Depreciation, as of Jun 2025, the value is 9.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.70 Cr. (Mar 2025) to 9.91 Cr., marking a decrease of 1.79 Cr..
• For Profit before tax, as of Jun 2025, the value is 3.33 Cr.. The value appears to be declining and may need further review. It has decreased from 5.62 Cr. (Mar 2025) to 3.33 Cr., marking a decrease of 2.29 Cr..
• For Tax %, as of Jun 2025, the value is 50.75%. The value appears to be increasing, which may not be favorable. It has increased from -35.94% (Mar 2025) to 50.75%, marking an increase of 86.69%.
• For Net Profit, as of Jun 2025, the value is 1.63 Cr.. The value appears to be declining and may need further review. It has decreased from 7.64 Cr. (Mar 2025) to 1.63 Cr., marking a decrease of 6.01 Cr..
• For EPS in Rs, as of Jun 2025, the value is 1.03. The value appears to be declining and may need further review. It has decreased from 4.83 (Mar 2025) to 1.03, marking a decrease of 3.80.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:23 am

Growth

Last Updated: September 5, 2025, 3:45 am

Balance Sheet

Last Updated: November 9, 2025, 1:58 pm

Below is a detailed analysis of the balance sheet data for Everest Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
• For Reserves, as of Sep 2025, the value is 561.00 Cr.. The value appears to be declining and may need further review. It has decreased from 581.00 Cr. (Mar 2025) to 561.00 Cr., marking a decrease of 20.00 Cr..
• For Borrowings, as of Sep 2025, the value is 309.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 265.00 Cr. (Mar 2025) to 309.00 Cr., marking an increase of 44.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 417.00 Cr.. The value appears to be improving (decreasing). It has decreased from 449.00 Cr. (Mar 2025) to 417.00 Cr., marking a decrease of 32.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 1,303.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,311.00 Cr. (Mar 2025) to 1,303.00 Cr., marking a decrease of 8.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 558.00 Cr.. The value appears to be declining and may need further review. It has decreased from 562.00 Cr. (Mar 2025) to 558.00 Cr., marking a decrease of 4.00 Cr..
• For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 5.00 Cr..
• For Investments, as of Sep 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 2.00 Cr..
• For Other Assets, as of Sep 2025, the value is 726.00 Cr.. The value appears to be declining and may need further review. It has decreased from 727.00 Cr. (Mar 2025) to 726.00 Cr., marking a decrease of 1.00 Cr..
• For Total Assets, as of Sep 2025, the value is 1,303.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,311.00 Cr. (Mar 2025) to 1,303.00 Cr., marking a decrease of 8.00 Cr..

Notably, the Reserves (561.00 Cr.) exceed the Borrowings (309.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Everest Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -2.28. This value is below the healthy minimum of 5. It has decreased from 11.42 (Mar 24) to -2.28, marking a decrease of 13.70.
• For Diluted EPS (Rs.), as of Mar 25, the value is -2.28. This value is below the healthy minimum of 5. It has decreased from 11.42 (Mar 24) to -2.28, marking a decrease of 13.70.
• For Cash EPS (Rs.), as of Mar 25, the value is 22.33. This value is within the healthy range. It has decreased from 31.89 (Mar 24) to 22.33, marking a decrease of 9.56.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 377.13. It has decreased from 378.38 (Mar 24) to 377.13, marking a decrease of 1.25.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 377.13. It has decreased from 378.38 (Mar 24) to 377.13, marking a decrease of 1.25.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,089.03. It has increased from 997.82 (Mar 24) to 1,089.03, marking an increase of 91.21.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 28.17. This value is within the healthy range. It has decreased from 37.18 (Mar 24) to 28.17, marking a decrease of 9.01.
• For PBIT / Share (Rs.), as of Mar 25, the value is 3.56. This value is within the healthy range. It has decreased from 16.69 (Mar 24) to 3.56, marking a decrease of 13.13.
• For PBT / Share (Rs.), as of Mar 25, the value is -3.98. This value is below the healthy minimum of 0. It has decreased from 13.42 (Mar 24) to -3.98, marking a decrease of 17.40.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -2.28. This value is below the healthy minimum of 2. It has decreased from 11.40 (Mar 24) to -2.28, marking a decrease of 13.68.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.28. This value is below the healthy minimum of 2. It has decreased from 11.40 (Mar 24) to -2.28, marking a decrease of 13.68.
• For PBDIT Margin (%), as of Mar 25, the value is 2.58. This value is below the healthy minimum of 10. It has decreased from 3.72 (Mar 24) to 2.58, marking a decrease of 1.14.
• For PBIT Margin (%), as of Mar 25, the value is 0.32. This value is below the healthy minimum of 10. It has decreased from 1.67 (Mar 24) to 0.32, marking a decrease of 1.35.
• For PBT Margin (%), as of Mar 25, the value is -0.36. This value is below the healthy minimum of 10. It has decreased from 1.34 (Mar 24) to -0.36, marking a decrease of 1.70.
• For Net Profit Margin (%), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 5. It has decreased from 1.14 (Mar 24) to -0.20, marking a decrease of 1.34.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -0.20. This value is below the healthy minimum of 8. It has decreased from 1.14 (Mar 24) to -0.20, marking a decrease of 1.34.
• For Return on Networth / Equity (%), as of Mar 25, the value is -0.60. This value is below the healthy minimum of 15. It has decreased from 3.01 (Mar 24) to -0.60, marking a decrease of 3.61.
• For Return on Capital Employeed (%), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 10. It has decreased from 3.69 (Mar 24) to 0.69, marking a decrease of 3.00.
• For Return On Assets (%), as of Mar 25, the value is -0.27. This value is below the healthy minimum of 5. It has decreased from 1.50 (Mar 24) to -0.27, marking a decrease of 1.77.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.15. This value is below the healthy minimum of 0.2. It has increased from 0.07 (Mar 24) to 0.15, marking an increase of 0.08.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has increased from 0.07 (Mar 24) to 0.27, marking an increase of 0.20.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.37. It has increased from 1.35 (Mar 24) to 1.37, marking an increase of 0.02.
• For Current Ratio (X), as of Mar 25, the value is 1.38. This value is below the healthy minimum of 1.5. It has decreased from 1.40 (Mar 24) to 1.38, marking a decrease of 0.02.
• For Quick Ratio (X), as of Mar 25, the value is 0.51. This value is below the healthy minimum of 1. It has decreased from 0.60 (Mar 24) to 0.51, marking a decrease of 0.09.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.18. This value is within the healthy range. It has increased from 3.51 (Mar 24) to 4.18, marking an increase of 0.67.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -109.56. This value is below the healthy minimum of 20. It has decreased from 52.48 (Mar 24) to -109.56, marking a decrease of 162.04.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 11.17. This value is below the healthy minimum of 20. It has decreased from 18.75 (Mar 24) to 11.17, marking a decrease of 7.58.
• For Earning Retention Ratio (%), as of Mar 25, the value is 209.56. This value exceeds the healthy maximum of 70. It has increased from 47.52 (Mar 24) to 209.56, marking an increase of 162.04.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 88.83. This value exceeds the healthy maximum of 70. It has increased from 81.25 (Mar 24) to 88.83, marking an increase of 7.58.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.89. This value is below the healthy minimum of 3. It has decreased from 4.60 (Mar 24) to 1.89, marking a decrease of 2.71.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 3. It has decreased from 1.82 (Mar 24) to 0.35, marking a decrease of 1.47.
• For Enterprise Value (Cr.), as of Mar 25, the value is 837.68. It has decreased from 1,623.58 (Mar 24) to 837.68, marking a decrease of 785.90.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.48. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.48, marking a decrease of 0.55.
• For EV / EBITDA (X), as of Mar 25, the value is 18.80. This value exceeds the healthy maximum of 15. It has decreased from 27.66 (Mar 24) to 18.80, marking a decrease of 8.86.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.39. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.39, marking a decrease of 0.65.
• For Retention Ratios (%), as of Mar 25, the value is 209.56. This value exceeds the healthy maximum of 70. It has increased from 47.51 (Mar 24) to 209.56, marking an increase of 162.05.
• For Price / BV (X), as of Mar 25, the value is 1.15. This value is within the healthy range. It has decreased from 2.75 (Mar 24) to 1.15, marking a decrease of 1.60.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.39. This value is below the healthy minimum of 1. It has decreased from 1.04 (Mar 24) to 0.39, marking a decrease of 0.65.
• For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.01, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness